Common Therapies for Basal Cell Carcinoma Offer Similar Survival

This article originally appeared here.
Share this content:
Common Therapies for Basal Cell Carcinoma Offer Similar Survival
Common Therapies for Basal Cell Carcinoma Offer Similar Survival

(HealthDay News) – For patients with superficial basal cell carcinoma (sBCC), treatment with imiquimod or photodynamic therapy (PDT) results in similar long-term tumor-free survival, according to a review published online May 21 in the British Journal of Dermatology.

Marieke H. Roozeboom, MD, from the Maastricht University Medical Centre in the Netherlands, and colleagues conducted a systematic literature review to determine residue, recurrence, and tumor-free survival for patients with sBCC treated with frequently used therapies. Thirty-six (14 randomized and 22 non-randomized) studies were included.

The researchers found that, based on 28 studies, the pooled estimates of percentages of sBCC with complete response 12 weeks after treatment were 86.2% for imiquimod and 79.0% for PDT. At one year, tumor-free survival was 87.3% for imiquimod and 84% for PDT, based on pooled estimates from 23 studies. Treatment results with 5-fluorouracil, surgical excision, and cryotherapy were reported by a small number of studies.

"Pooled estimates from randomized and non-randomized studies showed similar tumor-free survival at 1 year for imiquimod and PDT," the authors write. "There is a need for head-to-head comparison studies between PDT, imiquimod, and other treatments with long-term follow-up to enable better recommendations for optimal sBCC treatment."

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs